Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-07-05
2011-07-05
Nolan, Jason M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S619000, C514S617000, C514S532000, C514S529000, C562S507000, C562S433000, C564S163000
Reexamination Certificate
active
07973079
ABSTRACT:
Compounds that reduce serum retinol levels are used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods, compounds, and compositions to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions.
REFERENCES:
patent: 2526534 (1950-10-01), Britton et al.
patent: 4255152 (1981-03-01), Hewitt et al.
patent: 2006/0140953 (2006-06-01), Newell et al.
patent: 57-007480 (1982-01-01), None
patent: WO 2005/092062 (2005-10-01), None
patent: WO 2005100301 (2005-10-01), None
patent: WO-2005-116010 (2005-12-01), None
Thornton et al. Eye 2005, 19, 935-944.
http://www.mayoclinic.com/health/macular-degeneration/DS00284/DSECTION=treatments-and-drugs. Visited Jul. 26, 2010.
Byrn et al., Chapter 11 Hydrates and Solvates in Solid-State Chemistry of Drugs (2nd Ed.), 1999, 233-247.
Morissette et al. Adv. Drug Delivery Rev. 2004, 56, 275-300.
A.M. Rouhi, Chem. & Eng. News, Feb. 24, 2003, 81(8), 32-35.
Sandham et al. Bioorg. Med. Chem. Lett. 2007, 17, 4347-4350.
Kryuchkova et al. Izvestiya Vysshikh Uchebnykh Zavedenii, Khimiya i Khimicheskaya Tekhnologiya 1974, 17(7), 1104-6 (Abstract and structures from CAPLUS provided).
Nicola et al. Biochemical and Biophysical Research Communications 2007, 358(3), 686-691.
Ulven et al. J. Med. Chem. 2006, 49, 6638-6641.
Mohile et al., “Ionic liquids: efficient additives forCandida rugosalipase-catalysed enantioselective hydrolysis of butyl 2-(4-chlorophenoxy)propionate,” J. Mol. Catalysis B: Enzymatic 30:(5-6):185-188 (2004).
Motani, A. et al., “Identification and Characterization of a Non-Retinoid Ligand for Retinol-Binding Protein 4 Which Lowers Serum Retinol-Binding Protein 4 Levels In Vivo,” JBC Papers in Press, pp. 1-16, Jan. 15, 2009, http://www.jbc.org/cgi/doi/10.1074/jbc.M809654200.
PCT/US08/76499 Search Report dated Mar. 24, 2009.
Science IP Search dated Jul. 13, 2006.
Science IP Search dated Sep. 10, 2007.
Supplementary EP Search Report and Written Opinion 08834564 dated Nov. 10, 2010.
Bui Tam V.
Haddach Mustapha
Mata Nathan L.
Phan Kim B.
Nolan Jason M
Revision Therapeutics, Inc.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Methods and compounds for treating retinol-related diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compounds for treating retinol-related diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compounds for treating retinol-related diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2692312